# Natural Killer-cell Therapy for Acute Myeloid Leukemia

> **NCT04347616** · PHASE1,PHASE2 · TERMINATED · sponsor: **Radboud University Medical Center** · enrollment: 9 (actual)

## Conditions studied

- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, Relapsed, Adult

## Interventions

- **BIOLOGICAL:** UCB-NK cells
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT04347616
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-03
- **Primary completion:** 2026-01-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Stop funding
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04347616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04347616, "Natural Killer-cell Therapy for Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04347616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*